Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Pidilizumab (MDV9300) in Patients With Diffuse Large B-Cell Lymphoma Following First Remission

NCT02530125 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT02530125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02530125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Pidilizumab (MDV9300) in Patients With Diffuse Large B-Cell Lymphoma Following First Remission
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Terminated
Start date
September 30, 2015
Completion date
January 31, 2017
Enrollment
4 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

stage iii diffuse large b-cell lymphoma, stage iv diffuse large b-cell lymphoma